• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

HRT review finds increased risk of blood clots and stroke
Conclusion This updated Cochrane review has found that oral HRT increases risk of stroke and blood clots, and does not appear to reduce overall risk of cardiovascular disease or death during follow-up. More exploratory analyses suggested that HRT might reduce risk of death from heart disease or non-fatal heart attack if it was started within 10 years of menopause, but this finding needs further confirmation. The review was carried out using robust methods and the trials were of good quality. Its findings are in line with the previous version of the review, and also with other reviews. There are some points to note: Thi...
Source: NHS News Feed - March 10, 2015 Category: Consumer Health News Tags: Heart/lungs Medication Source Type: news

Stroke in Women
This article reviews sex differences in stroke risk and presentation, with a particular emphasis on the unique risk factors women experience throughout the lifespan. RECENT FINDINGS Although prior studies suggested women have worse outcomes after stroke, it is now clear that age, prestroke functional status, and comorbidities explain many of the differences between men and women in stroke severity, functional outcomes, and mortality. Several meta-analyses and large cohort studies have evaluated the risk factors for women related to reproductive factors and found that fewer years between menarche and menopause, pregnancy...
Source: CONTINUUM: Lifelong Learning in Neurology - April 1, 2020 Category: Neurology Tags: REVIEW ARTICLES Source Type: research

A systematic review and meta-regression analysis to examine the ‘timing hypothesis’ of hormone replacement therapy on mortality, coronary heart disease, and stroke
ConclusionYounger initiation of HRT may be effective in reducing death and cardiac events. However, younger HRT initiators remained at an increased risk of stroke, TIA and systemic embolism and this risk increased as average age increased. Younger menopausal women using HRT to treat vasomotor symptoms do not appear to be at an increased risk of dying or experiencing CHD events.
Source: IJC Heart and Vasculature - January 18, 2019 Category: Cardiology Source Type: research

Study: Different hormone therapy formulations may pose different risks for heart attack and stroke
(Cedars-Sinai Medical Center) Post-menopausal women whose doctors prescribe hormone replacement therapy for severe hot flashes and other menopause symptoms may want to consider taking low doses of FDA-approved bioidentical forms of estrogen or getting their hormones via a transdermal patch. A new observational study shows bioidentical hormones in transdermal patches may be associated with a lower risk of heart attack and FDA-approved products -- not compounded hormones -- may be associated with a slightly lower risk of stroke compared to synthetic hormones in pill form.
Source: EurekAlert! - Medicine and Health - September 18, 2013 Category: Global & Universal Source Type: news

Different risks for heart attack and stroke posed by different hormone therapy formulations
Post-menopausal women whose doctors prescribe hormone replacement therapy for severe hot flashes and other menopause symptoms may want to consider taking low doses of Food and Drug Administration-approved bioidentical forms of estrogen or getting their hormones via a transdermal patch. A new observational study shows bioidentical hormones in transdermal patches may be associated with a lower risk of heart attack and FDA-approved products -- not compounded hormones -- may be associated with a slightly lower risk of stroke compared to synthetic hormones in pill form...
Source: Health News from Medical News Today - September 20, 2013 Category: Consumer Health News Tags: Menopause Source Type: news

Stroke risk could be higher for women who don't use hormone replacement therapy, study suggests 
Women who go into early menopause or do not use hormone replacement therapy could be at a higher risk of stroke, a study found.
Source: the Mail online | Health - February 2, 2023 Category: Consumer Health News Source Type: news

Migraines linked to increased heart disease risk in women
Conclusion This study shows a strong link between migraine and cardiovascular disease, extending the link already found between migraine and stroke. However, many questions remain. We don't know if the results are relevant to men who have migraines, as all the people in the study were women. We also don't know if the results apply to non-white populations, as most of the women in the study were white. Previous studies on stroke have shown that the group at highest risk is who get an "aura" before a migraine – sensation(s) that tells them the migraine is on its way. But this study did not ask people about aura...
Source: NHS News Feed - June 1, 2016 Category: Consumer Health News Tags: Heart/lungs Neurology Source Type: news

Transient ischemic attacks in post-menopausal women with history of migraines have lower risk for subsequent ischemic strokes (P2.306)
CONCLUSIONS: The risk of ischemic stroke is lower following TIA in women with migraine history (compared with those without migraine) suggesting potentially different pathophysiology in such women.Disclosure: Dr. Rahman has nothing to disclose. Dr. Malik has nothing to disclose. Dr. Thomas has nothing to disclose. Dr. Qureshi has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Rahman, H., Malik, A., Thomas, A., Qureshi, A. Tags: Cerebrovascular Disease and Interventional Neurology: Education and TIA Source Type: research

A Post-Hoc Assessment of Current Hormone Therapy on Revascularization Risk in Women: The Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST) (P03.168)
CONCLUSIONS: We found that women on current HRT have lower periprocedural risk associated with CAS or CEA than non-users, but little difference in risk after the procedural period. The mechanism for this unexpected finding is elusive. We urge caution in the interpretation of this post-hoc observation and encourage replication or refutation by other revascularization studies with similar data.Disclosure: Dr. Mackey has nothing to disclose. Dr. Lutsep has received personal compensation for serving on Consultant/Advisory Boards for Concentric Medical/Stryker, Co-Axia, and AGA Medical. Dr. Lutsep has received personal compensa...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Mackey, A., Lutsep, H., Milot, G., Voeks, J., Howard, V., Hughes, S., Tom, M., Longbottom, M., Sheffet, A., Brott, T. Tags: P03 Cerebrovascular Disease III Source Type: research

HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT.
Abstract ABSTRACT Hormone replacement therapy (HRT) remains the gold standard for treatment of climacteric symptoms in menopausal women; it is relatively safe in healthy subjects for at least 5 years, provided it had been initiated before the age of 60 years and/or within 10 years from menopause. Estrogen probably adds some cardioprotection, that can, however, be obscured by progestogens, especially medroxyprogesterone acetate (MPA). Oral HRT is associated with an increased risk of venous thromboembolism (VTE), gallbladder disease and possibly stroke. The increased occurrence of all these events can be prevented b...
Source: Climacteric - July 19, 2013 Category: Geriatrics Authors: L'hermite M Tags: Climacteric Source Type: research

Can HRT in early menopause cut heart disease risk?
ConclusionThis double-blind RCT found that women taking HRT less than six years after the menopause had slower artery wall thickening than those taking a placebo. This represented the main measure of atherosclerosis progression tested; other measures showed no difference, so the results were not as conclusive as they could have been. Women taking HRT 10 or more years after menopause also showed no difference in atherosclerosis progression compared with a placebo, further complicating the picture.An important limitation of this study is the lack of a patient relevant endpoint, such as cardiovascular events or mortality. Pre...
Source: NHS News Feed - April 1, 2016 Category: Consumer Health News Tags: Heart/lungs Medication Source Type: news

Vascular risk factors for male and female urgency urinary incontinence at age 68 years from a British birth cohort study
ConclusionMultifactorial mechanisms lead to UUI and vascular risk factors may contribute to the pathogenesis of bladder overactivity in addition to higher BMI. Severe UUI appears to be a distinct presentation with more specific contributory mechanisms than milder UUI.
Source: BJU International - March 7, 2018 Category: Urology & Nephrology Authors: Alex Tsui, Diana Kuh, Linda Cardozo, Daniel Davis Tags: Original Article Source Type: research

Sex and Gender Considerations in Episodic Migraine
AbstractPurpose of ReviewWe seek to update readers on recent advances in our understanding of sex and gender in episodic migraine with a two part series. In part 1, we examine migraine epidemiology in the context of sex and gender, differences in symptomatology, and the influence of sex hormones on migraine pathophysiology (including CGRP). In part 2, we focus on practical clinical considerations for sex and gender in episodic migraine by addressing menstrual migraine and the controversial topic of hormone-containing therapies. We make note of data applicable to gender minority populations, when available, and summarize kn...
Source: Current Pain and Headache Reports - June 9, 2022 Category: Neurology Source Type: research

In recently postmenopausal women, HRT reduced a composite of death, MI, or heart failure at 10 years.
CONCLUSION In recently postmenopausal women, hormone replacement therapy reduced a composite of death, myocardial infarction, or heart failure after 10 years of therapy and an additional 6 years of follow-up.Hormone replacement therapy (HRT) vs no HRT in recently postmenopausal women†OutcomesEvent ratesAfter 10 y of therapyHRTNo HRTRRR (95% CI)NNT (CI)Death, MI, or HF‡3.2%6.5%50% (11 to 72)31 (22 to 144)At 16 yDeath, MI, or HF§6.6%11%37% (4 to 59)26 (17 to 251)†HF = heart failure; MI = myocardial infarction; other abbreviations defined in Glossary. RRR, NNT, and CI calculated from event rates and hazard ratios in ar...
Source: Annals of Internal Medicine - February 19, 2013 Category: Internal Medicine Authors: Cheung AM Tags: Ann Intern Med Source Type: research

Hormone replacement therapy in menopause
Embora o estrógeno já esteja disponível para venda há mais de seis décadas, as mulheres ainda permanecem confusas quanto ao risco e aos benefícios da terapia hormonal na menopausa (THM), terapia estrogênica isolada ou associada a progestágenos. A publicação de estudos controlados, randomizados, como o Heart and Estrogen/progestin Replacement Study (HERS) e Women’s Health Initiative (WHI), intensificou essa controvérsia risco/benefício. Milhares de mulheres são tratadas com THM para alívio dos sintomas menopausais, incluindo sintomas vasomotores e sudorese, principal indicação da estrogenoterapia. Outras p...
Source: Arquivos Brasileiros de Endocrinologia e Metabologia - May 14, 2014 Category: Endocrinology Source Type: research

Pages: 1  2  3  4  5  6  7  8